BioCentury
ARTICLE | Company News

CDC panel snubs AZ's FluMist

June 24, 2016 12:19 AM UTC

CDC's Advisory Committee on Immunization Practices (ACIP) recommended against use of FluMist from AstraZeneca plc (LSE:AZN; NYSE:AZN) to prevent seasonal influenza during the 2016-17 flu season. The intranasal live attenuated influenza vaccine (LAIV) is the only non-injection-based flu vaccine available in the U.S.

CDC said ACIP based its vote on weak efficacy data in children aged 2-17 in the last three flu seasons. The agency said FluMist showed no measurable protective benefit in the 2015-16 season, based on an estimated 3% vaccine effectiveness rate in that age group. ...